drugset / Trial / NCT04483544
Pembrolizumab and Olaparib in Cervical Cancer Patients
Phase 2
Terminated
8 enrolled
Baptist Health South Florida
Florida Department of Health · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
Timeline
- Start
- 2020-12-03
- Primary completion
- 2024-12-12
- Completion
- 2024-12-12
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual related to change in standard of care treatment for this population.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |